Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development

Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) have been recently effective for diabetes. Among them, subcutaneous injection and oral form of semaglutide (Rybelsus) are in focus, in which the latter has been examined in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) studies. Rybelsus could been invented for absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, due to 30-year process of innovation by Novo Nordisk. It shows clinical effects for diabetes and obesity. For PIONEER 9 and 10 trials, efficacy and safety were shown for 3, 7 or 14 mg of Rybelsus equivalent to subcutaneous liraglutide and subcutaneous dulaglutide for 52 weeks.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.